UCLA’s Kidney Cancer Program offers the latest and most advanced care for kidney cancer. Our physicians are trained in urologic oncology and have been consistently ranked among the top kidney cancer practitioners in the United States. Additionally, our doctors are part of The UCLA Institute of Urologic Oncology (the "IUO") and its multidisciplinary team of world-renowned physicians and scientists who are working together to personalize patient care and to develop revolutionary treatments for patients diagnosed with kidney cancer.
The Kidney and Kidney Cancers
The UCLA Kidney Cancer Program prides itself on the achievements made in its state-of-the-art research and translational laboratories. Our highly experienced and dedicated basic science researchers work diligently to develop new, more effective treatments for kidney cancer and have pioneered numerous medical advances.
For decades, UCLA’s Kidney Cancer Program has prided itself on being able to offer patients access to ground-breaking experimental drugs in its Clinical Trials Program that allows patients to receive tomorrow’s approved drugs today. Until such time as a cure for this disease is found, the primary objective is focused on providing first-rate care for our patients, while making it possible for them to carry on a high quality of life.
Kidney cancer is cancer that originates in the kidneys. According to the American Cancer Society, this year approximately 62,700 people in the United States will be diagnosed with kidney cancer and about 14,240 people will die from this disease. Kidney cancer is among the 10 most common cancers in both men and women, and the risk for developing kidney cancer is higher in men than in women.
More information about types of kidney cancer, kidney anatomy and function >
Innovations in Treating Bladder and Kidney Cancer. UCLA urologist, Karim Chamie, MD, MSHS, presented a live-streaming webinar to discuss new cancer treatments.
Unfortunately, kidney cancer rarely causes visible signs or symptoms in its early stages. In the later stages, the most common sign of kidney cancer (both renal cell and transitional cell cancers) is blood in the urine (hematuria). Most of the time kidney cancer is found incidentally, during physical examinations for other problems, by imaging studies such as ultrasound, CAT scan or MRI. You may notice the blood when you urinate, or your doctor may detect blood from a urinalysis, a test that specifically checks the contents of your urine.
More information about kidney cancer symptoms >
In the past, kidney cancer / Renal Cell Carcinoma (RCC) was diagnosed only after the tumors had become quite large or symptoms of flank pain, blood in the urine or palpable mass in the abdomen developed. Today, most RCC are now found incidentally during examinations for other problems or during imaging studies such as ultrasound, CAT scan or MRI. Early diagnosis of kidney cancer is important to successful treatment. For more information about kidney cancer diagnosis, grading and staging >>
The UCLA Kidney Cancer Program offers a variety of innovative treatment options to patients who have been diagnosed with kidney cancer, including standard, minimally invasive and robotic-assisted kidney-sparing surgery, as well as clinical trials.
UCLA has been a pioneer in the innovative, multidisciplinary, translational approach to care, including:
The management of kidney cancer requires extensive collaboration among specialists. The UCLA Kidney Cancer Program holds bi-weekly conferences with a multidisciplinary team that provides a forum with diverse, specialized perspectives for deciding upon the best option for each individual patient.
More information about kidney cancer treatment at UCLA >
Clinical trials are essential for developing new methods of preventing, diagnosing and treating kidney cancer. The UCLA Kidney Cancer Program offers patients access to ground-breaking experimental drugs in its Clinical Trials Program that allows patients to receive tomorrow’s approved drugs today. Our UCLA doctors are able to provide access to new therapies at earlier stages of the disease. Using our research discoveries in the field of immunotherapy, work is currently under way on a targeted vaccine for kidney cancer that has been in development for the past decade.
The UCLA Bladder Cancer Program, in conjunction with the Jonsson Comprehensive Cancer Center and the UCLA Institute of Urologic Oncology, is committed to ongoing kidney cancer research in a quest to develop new treatments for and offer ground-breaking clinical trials to all UCLA kidney cancer patients, along with a commitment to educate and train the next generation of leading physician-scientists. UCLA was an early innovator in treatments that bring the patient’s immune system to bear against cancer. Breakthroughs in immunotherapy are revolutionizing the treatment of genitourinary cancer, with new treatment options imminent for patients with kidney cancer.
Learn more about our research >